The phase III DAWNA-1 trial met its primary endpoint of improved progression-free survival with dalpiciclib added to fulvestrant in previously treated HR-positive, HER2-negative advanced breast cancer, signaling a new option for combination therapy with a CDK4/6 inhibitor and endocrine therapy.